Raltegravir is effective for HIV-positive children, teens

01/8/2012 | United Press International

A national clinical trial of 96 HIV-positive children and adolescents showed that 53% of them achieved an undetectable amount of HIV in their blood after 24 weeks of treatment with raltegravir, which was recently approved by the FDA for use in children. The drug had no significant toxicities or interactions with other HIV drugs, the lead researcher said in a statement.

View Full Article in:

United Press International

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY